Literature DB >> 20135207

Model analysis of the concentration-dependent permeability of P-gp substrates.

Tatsuhiko Tachibana1, Satoshi Kitamura, Motohiro Kato, Tetsuya Mitsui, Yoshiyuki Shirasaka, Shinji Yamashita, Yuichi Sugiyama.   

Abstract

PURPOSE: Recently, it was reported that the apparent Michaelis-Menten constant (Km(app)) of a P-glycoprotein (P-gp) substrate, defined for the extracellular substrate concentration, increases as the P-gp expression level in the cell increases. By its nature, the Km value should not depend on the level of P-gp expression. The purpose of this study is to establish a model which can estimate the Km value independent of the P-gp expression level in cells.
METHODS: The previously reported concentration-dependent permeability of verapamil, quinidine, and vinblastine in MDR1-MDCKII, P-gp-highly induced Caco-2, P-gp-induced Caco-2, normal Caco-2, and MDR1-knockdown Caco-2 cells data were analyzed using a model in which the Km value was defined for the intracellular substrate concentration.
RESULTS: The estimated Km values defined for the substrate concentration inside the cells were almost the same among various cells with different levels of P-gp expression. The estimated Vmax values were approximately proportional to the P-gp expression level.
CONCLUSION: The established kinetic model was found to be rational based on the results that the Km values of P-gp substrates were about the same for cells expressing various levels of P-gp, while the Vmax values were proportional to the expression levels of P-gp.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20135207     DOI: 10.1007/s11095-009-0026-9

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  15 in total

Review 1.  The gut as a barrier to drug absorption: combined role of cytochrome P450 3A and P-glycoprotein.

Authors:  Y Zhang; L Z Benet
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

2.  Decrease in intracellular concentration causes the shift in Km value of efflux pump substrates.

Authors:  Timo Korjamo; Heidi Kemiläinen; Aki T Heikkinen; Jukka Mönkkönen
Journal:  Drug Metab Dispos       Date:  2007-06-04       Impact factor: 3.922

3.  Pharmacokinetics of pafenolol after i.v. and oral administration of three separate doses of different strength to man.

Authors:  C G Regardh; A Heggelund; K Kylberg-Hanssen; P Lundborg
Journal:  Biopharm Drug Dispos       Date:  1990-10       Impact factor: 1.627

4.  Celiprolol: pharmacokinetics and duration of pharmacodynamic activity.

Authors:  F S Caruso; H D Doshan; P H Hernandez; R Costello; W Applin; E S Neiss
Journal:  Br J Clin Pract Suppl       Date:  1985-06

5.  Evidence for intestinal secretion as an additional clearance pathway of talinolol enantiomers: concentration- and dose-dependent absorption in vitro and in vivo.

Authors:  U Wetterich; H Spahn-Langguth; E Mutschler; B Terhaag; W Rösch; P Langguth
Journal:  Pharm Res       Date:  1996-04       Impact factor: 4.200

6.  Dose-dependent increase of saquinavir bioavailability by the pharmaceutic aid cremophor EL.

Authors:  Meret Martin-Facklam; Jürgen Burhenne; Reinhard Ding; Ruth Fricker; Gerd Mikus; Ingeborg Walter-Sack; Walter E Haefeli
Journal:  Br J Clin Pharmacol       Date:  2002-06       Impact factor: 4.335

7.  Enhanced oral bioavailability of paclitaxel by coadministration of the P-glycoprotein inhibitor KR30031.

Authors:  Jong Soo Woo; Chang Hyun Lee; Chang Koo Shim; Sung-Joo Hwang
Journal:  Pharm Res       Date:  2003-01       Impact factor: 4.200

8.  Effect of P-glycoprotein expression levels on the concentration-dependent permeability of drugs to the cell membrane.

Authors:  Yoshiyuki Shirasaka; Toshiyasu Sakane; Shinji Yamashita
Journal:  J Pharm Sci       Date:  2008-01       Impact factor: 3.534

Review 9.  Importance of P-glycoprotein at blood-tissue barriers.

Authors:  Martin F Fromm
Journal:  Trends Pharmacol Sci       Date:  2004-08       Impact factor: 14.819

10.  Scaling of in vitro membrane permeability to predict P-glycoprotein-mediated drug absorption in vivo.

Authors:  Yoshiyuki Shirasaka; Yoshie Masaoka; Makoto Kataoka; Shinji Sakuma; Shinji Yamashita
Journal:  Drug Metab Dispos       Date:  2008-02-14       Impact factor: 3.922

View more
  26 in total

Review 1.  Coexistence of passive and carrier-mediated processes in drug transport.

Authors:  Kiyohiko Sugano; Manfred Kansy; Per Artursson; Alex Avdeef; Stefanie Bendels; Li Di; Gerhard F Ecker; Bernard Faller; Holger Fischer; Grégori Gerebtzoff; Hans Lennernaes; Frank Senner
Journal:  Nat Rev Drug Discov       Date:  2010-08       Impact factor: 84.694

Review 2.  Physiologically based pharmacokinetic modelling of drug penetration across the blood-brain barrier--towards a mechanistic IVIVE-based approach.

Authors:  Kathryn Ball; François Bouzom; Jean-Michel Scherrmann; Bernard Walther; Xavier Declèves
Journal:  AAPS J       Date:  2013-06-20       Impact factor: 4.009

3.  Predicting efflux ratios and blood-brain barrier penetration from chemical structure: combining passive permeability with active efflux by P-glycoprotein.

Authors:  Elena Dolghih; Matthew P Jacobson
Journal:  ACS Chem Neurosci       Date:  2012-12-11       Impact factor: 4.418

4.  Consideration of the Unbound Drug Concentration in Enzyme Kinetics.

Authors:  Nigel J Waters; R Scott Obach; Li Di
Journal:  Methods Mol Biol       Date:  2021

5.  Case Study 7: Transporters Case Studies-In Vitro Solutions for Translatable Outcomes.

Authors:  Sid Bhoopathy; Chris Bode; Vatsala Naageshwaran; Erica Weiskircher-Hildebrandt; Venkata Mukkavilli; Ismael J Hidalgo
Journal:  Methods Mol Biol       Date:  2021

6.  Prediction of Drug Clearance from Enzyme and Transporter Kinetics.

Authors:  Priyanka R Kulkarni; Amir S Youssef; Aneesh A Argikar
Journal:  Methods Mol Biol       Date:  2021

Review 7.  Novel insights into the organic solute transporter alpha/beta, OSTα/β: From the bench to the bedside.

Authors:  James J Beaudoin; Kim L R Brouwer; Melina M Malinen
Journal:  Pharmacol Ther       Date:  2020-04-02       Impact factor: 12.310

Review 8.  Intracellular drug concentrations and transporters: measurement, modeling, and implications for the liver.

Authors:  X Chu; K Korzekwa; R Elsby; K Fenner; A Galetin; Y Lai; P Matsson; A Moss; S Nagar; G R Rosania; J P F Bai; J W Polli; Y Sugiyama; K L R Brouwer
Journal:  Clin Pharmacol Ther       Date:  2013-04-10       Impact factor: 6.875

Review 9.  ITC recommendations for transporter kinetic parameter estimation and translational modeling of transport-mediated PK and DDIs in humans.

Authors:  M J Zamek-Gliszczynski; C A Lee; A Poirier; J Bentz; X Chu; H Ellens; T Ishikawa; M Jamei; J C Kalvass; S Nagar; K S Pang; K Korzekwa; P W Swaan; M E Taub; P Zhao; A Galetin
Journal:  Clin Pharmacol Ther       Date:  2013-02-25       Impact factor: 6.875

10.  Modeling cyclosporine A inhibition of the distribution of a P-glycoprotein PET ligand, 11C-verapamil, into the maternal brain and fetal liver of the pregnant nonhuman primate: impact of tissue blood flow and site of inhibition.

Authors:  Alice Ban Ke; Sara Eyal; Francisco S Chung; Jeanne M Link; David A Mankoff; Mark Muzi; Jashvant D Unadkat
Journal:  J Nucl Med       Date:  2013-01-28       Impact factor: 10.057

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.